Head & Neck Cancer: Overview & Staging
Cancer Subtypes by Subsite
| Subsite | Key Features |
|---|
| Oral Cavity | Lips, tongue, floor of mouth, hard palate; tobacco/alcohol/betel nut risk |
| Oropharynx | Tonsils, base of tongue, soft palate; HPV-16 driven — rising incidence |
| Hypopharynx | Pyriform sinus, posterior pharyngeal wall; poor prognosis, often late stage |
| Larynx | Supraglottis/glottis/subglottis; smoking dominant risk; hoarseness early sign |
| Nasopharynx | EBV-associated; high in South/SE Asian populations; neck mass common presentation |
| Thyroid | Papillary (most common, excellent prognosis); follicular; medullary; anaplastic |
| Salivary Gland | Parotid, submandibular, sublingual; mucoepidermoid/adenoid cystic most common |
| Skin (H&N) | SCC/BCC; UV exposure — high risk in GCC due to outdoor work/sun exposure |
TNM Staging System (AJCC 8th Ed)
| Category | Description |
|---|
| T1 | Tumour ≤2cm, confined to primary site |
| T2 | Tumour 2–4cm or limited local extension |
| T3 | Tumour >4cm or significant local extension |
| T4a | Moderately advanced local disease |
| T4b | Very advanced — encases carotid artery |
| N0 | No regional node involvement |
| N1–N3 | Increasing nodal burden (size/number/bilaterality) |
| M0/M1 | No/distant metastases (lung most common) |
ℹOropharynx HPV staging: Separate staging system — p16+ tumours staged differently. Stage I HPV+ = T1–T2, N0–N1 (equivalent to Stage III–IVA in HPV−). Better prognosis despite nodal disease.
HPV-Associated Oropharyngeal Cancer
- Rising globally — now accounts for 70–80% of oropharyngeal SCC in Western countries; increasing in GCC
- Younger patients (40s–50s), often non-smokers; sexual transmission (HPV-16)
- Better prognosis — 3-year OS ~85% vs 60% HPV−
- Presentation: Neck mass (cystic, often large) as first sign — primary may be small/occult
- Diagnosis: p16 immunohistochemistry as surrogate HPV marker; HPV ISH for confirmation
- Treatment de-escalation trials ongoing — reduced RT dose/volume in selected HPV+ patients
- Nursing implication: Psychological impact — STI-linked cancer; sensitive counselling required; partner anxiety
Nasopharyngeal Cancer (NPC) — EBV-Associated
- EBV (Epstein-Barr Virus) driven — WHO Type III (undifferentiated) most common in Asia
- High in: South Chinese, Filipino, Thai, Malaysian, Vietnamese populations — major GCC expat groups
- Epidemiology: Incidence 15–50/100,000 in endemic regions vs 1/100,000 in Western populations
- Presentation: Cervical lymphadenopathy, epistaxis, nasal obstruction, serous otitis media, cranial nerve palsy (late)
- Staging: EBV DNA titre (plasma) — prognostic and treatment response monitoring
- Treatment: Chemoradiotherapy (cisplatin-based) — surgery not primary treatment
- Nursing: Educate about EBV monitoring, post-RT surveillance endoscopy, EBV DNA titres
Diagnostic Pathway
Initial Assessment
- Full history: tobacco/alcohol/HPV risk, betel nut/gutka use, occupational exposure
- Clinical examination: bimanual palpation, laryngoscopy (flexible nasendoscopy)
- Fine needle aspiration cytology (FNAC) for neck node — do NOT excise without diagnosis
- Core biopsy if FNAC inconclusive
Staging Investigations
- CT neck/chest/abdomen: locoregional staging, lung mets
- MRI: soft tissue detail — tongue base, parapharyngeal, perineural invasion
- PET-CT: distant metastases, unknown primary workup, post-treatment response
- Panendoscopy (EUA): bimanual examination + biopsy under GA — gold standard
MDT Components
- Head & neck surgeon (ENT/maxillofacial)
- Clinical oncologist (RT) + medical oncologist (chemo)
- Radiologist + nuclear medicine
- Histopathologist
- Speech & language therapist (SLT)
- Dietitian + clinical nurse specialist (CNS)
- Dental/maxillofacial prosthodontist (pre-RT dental clearance)
- Psychologist/social worker
- Physiotherapist
Performance Status Assessment
ECOG Performance Status
| Score | Description | Treatment implication |
|---|
| 0 | Fully active | Full treatment — surgery + CRT |
| 1 | Restricted in strenuous activity | Standard treatment |
| 2 | Ambulatory >50% waking hours | Caution — weekly cisplatin preferred |
| 3 | Confined to bed/chair >50% | Palliative intent — reduced dose RT |
| 4 | Completely disabled | Best supportive care |
Nursing Assessment at Diagnosis
- Weight/nutritional status: BMI, % weight loss, MUST score
- Swallowing baseline: SLT assessment before treatment starts
- Dental assessment: Pre-RT dental extractions to prevent osteoradionecrosis
- Social history: Carer support, language needs, cultural considerations
- Hearing baseline: Audiogram before platinum chemotherapy
- Renal function: eGFR before cisplatin — hold if eGFR <50
- Psychological: Distress thermometer, anxiety/depression screening
Surgical Nursing Care
🚨
EMERGENCY: Free flap compromise is a surgical emergency — any sign of vascular compromise requires IMMEDIATE surgical re-exploration. Do not delay to await consultant review. Activate emergency protocol NOW.
Total Laryngectomy Nursing
⚠PERMANENT TRACHEOSTOMY: After total laryngectomy, the trachea is permanently separated from the mouth/nose. This patient breathes ONLY through their neck stoma. Emergency bag/mask ventilation via face is INEFFECTIVE.
Stoma Care
- Clean stoma 2–4x daily with normal saline and non-woven gauze
- Laryngectomy tube/stoma button: change per protocol (typically every 3–7 days)
- HME (Heat Moisture Exchanger) filter — essential for humidification; change every 24h
- Humidification: nebulised saline 4–6x daily to prevent crusting/mucus plugging
- Suction: size 14 Fr catheter, insert <5cm only, sterile technique, pre/post-oxygenate
- Showering: Waterproof laryngectomy bib (Laryngofoan/Romet) or shower shield — water must NOT enter stoma
Lifelong Voice Rehabilitation
- TEP (Tracheoesophageal Prosthesis): Provox/Blom-Singer valve; primary (at surgery) or secondary (post-op); best voice outcomes
- Electrolarynx: Electronic device placed against cheek/neck; immediate post-op use
- Oesophageal speech: Air injection technique — requires training, less common now
- Emergency ID Card: Patient carries laryngectomy identity card — instruct all patients, issue pre-discharge
Free Flap Reconstruction Monitoring
Common Flaps in H&N Surgery
- Radial Forearm Free Flap (RFFF): Thin, pliable — tongue/floor of mouth/pharynx
- ALT (Anterolateral Thigh): Large defects — pharyngeal reconstruction
- Fibula Free Flap: Mandibular reconstruction — includes bone + skin paddle
- Pectoralis Major Pedicled Flap: Salvage/high-risk patients
Hourly Flap Monitoring (First 72h)
Colour — Pink/normal skin toneNORMALPale/Blue = ALERT
Temperature — Warm to touchWARMCold = ALERT
Capillary Refill — <2 seconds<2s>3s = ALERT
Doppler Signal — Audible triphasicTriphasicAbsent = ALERT
Turgor/Swelling — Slight firmness normalSoftTense/Hard = ALERT
🚨ANY FAIL: Do NOT wait. Call surgeon immediately. Window for salvage is typically 4–6h from arterial occlusion.
Neck Dissection Nursing Care
Types
- Selective Neck Dissection (SND): Levels I–III or II–IV removed; spinal accessory nerve preserved
- Modified Radical Neck Dissection (MRND): All 5 levels; preserves CN XI, IJV, SCM
- Radical Neck Dissection: All 5 levels + CN XI + IJV + SCM removed — rare now
Post-operative Drain Management
- Redivac/Blake drain: record volume hourly initially, then 4-hourly
- Normal: sero-sanguineous, decreasing volume; remove when <30ml/24h
- Ensure patency — do not kink; gentle milking if blocked
Chyle Leak Recognition
⚠Chyle Leak Signs: Milky-white drain fluid (especially after first oral intake), sudden increase in drain volume (>200ml/24h), triglycerides in fluid >1.1mmol/L. Notify surgical team immediately.
- Management: nil fat diet → medium-chain triglyceride (MCT) diet → TPN → surgical ligation if conservative fails
- Monitor for hypoalbuminaemia, electrolyte imbalance, immunosuppression with prolonged chyle loss
Shoulder Drop (CN XI Injury)
- Spinal accessory nerve (CN XI) damage → trapezius weakness → drooping shoulder, limited abduction
- Physiotherapy referral: shoulder exercises — essential from post-op day 1–2 when drain removed
- Pendulum exercises, progressive resistance; shoulder harness/support initially
- Assess grip strength, shoulder range of motion at each review
Mandibulectomy & Oral Cavity Surgery
Post-operative Oral Care
- Chlorhexidine 0.12% mouthwash every 2h (awake) from Day 1
- Saline rinse after every meal — remove debris from suture lines
- Soft suction toothbrush when tolerated — avoid disrupting intraoral suture lines
- Inspect oral cavity with torch daily — early wound dehiscence/infection detection
- Fistula surveillance: saliva tracking through wound to skin = orocutaneous fistula — surgical team alert
Nutrition Post-oral Surgery
- NG tube or PEG usually placed intra-operatively for large resections
- Dietitian review within 24h of surgery
- High-protein enteral feeds: 1.5–2g/kg/day protein target
- Transition to oral diet: SLT-guided, texture-modified (IDDSI framework)
- Dental prosthesis fitting: obturator for palate defects — coordinate with dental team
Tracheostomy Management (Temporary)
- Most oral cavity and oropharyngeal surgery involves temporary tracheostomy (airway protection)
- Cuffed tube initially → uncuffed/fenestrated → cap trial → decannulation pathway
- Document cuff pressures (20–30 cmH₂O), inner tube cleaning 4-hourly
- Decannulation when: no aspiration on cap trial, adequate cough, secure airway
Post-operative Nursing Observation Bundle (H&N Surgery)
| Parameter | Frequency | Action Threshold |
|---|
| Flap monitoring (colour, temp, cap refill, Doppler) | Hourly ×72h, then 4-hourly | Any deterioration — immediate surgical review |
| Drain volume and character | Hourly initially, 4-hourly when stable | Milky fluid / >200ml/h — chyle leak protocol |
| Airway/tracheostomy patency | Continuous monitoring, suction PRN | Desaturation SpO₂<94%, stridor — airway emergency |
| Haemoglobin / haematocrit | Day 1, 3, then as indicated | Hb <80g/L — transfusion discussion; <70 transfuse |
| Blood pressure management | Hourly ×24h then 4-hourly | MAP >80mmHg target for flap perfusion |
| Anticoagulation (VTE prophylaxis) | LMWH from Day 1 (surgeon decision) | Avoid over-anticoagulation — risk flap haematoma |
| Temperature | 4-hourly | >38.5°C post-Day 3: wound/chest infection, anastomotic leak |
| Pain assessment (NRS) | 2-hourly initially, then 4-hourly | NRS >6: escalate analgesia; document; avoid NSAID in renal impairment |
Concurrent Chemoradiotherapy (CRT)
Cisplatin Regimens
| Regimen | Details | Notes |
|---|
| Weekly Cisplatin | 40 mg/m² IV every week × 6–7 weeks | Preferred — less systemic toxicity, more predictable, easier dose management |
| 3-Weekly Cisplatin | 100 mg/m² IV weeks 1 and 4 (or 1,4,7) | Historical standard; higher nausea/renal risk; some evidence of higher mucosal toxicity |
| Cetuximab | Loading dose 400 mg/m² then 250 mg/m² weekly | Alternative in cisplatin-ineligible; anti-EGFR; acneiform rash monitoring essential |
ℹWeekly vs 3-weekly cisplatin: Meta-analyses suggest equivalent locoregional control with weekly 40mg/m² but significantly less ototoxicity, nephrotoxicity, and haematological toxicity. Most GCC centres now use weekly protocol.
Cisplatin Hydration Protocol
- Pre-hydration: 1000ml 0.9% NaCl with KCl 20mmol + MgSO₄ 8mmol over 60–120 min BEFORE cisplatin
- Cisplatin infusion: Diluted in 500ml 0.9% NaCl — infuse over 30–60 min (weekly); protect from light
- Post-hydration: 1000ml 0.9% NaCl over 1–2h AFTER cisplatin
- Ensure urine output ≥100ml/h during infusion and 2h post — insert urinary catheter if unable to monitor
- Mannitol: 20% mannitol 100ml IV if urine output <100ml/h (per protocol)
- Electrolytes: Replace Mg, K as needed (cisplatin causes Mg/K wasting)
- Total fluid load: ~3L per cisplatin day — assess cardiac status before
Antiemetic Prophylaxis (Triple Therapy)
- Highly Emetogenic Protocol (cisplatin):
- 1. 5-HT₃ antagonist: Ondansetron 8mg IV (or Granisetron) — 30 min before cisplatin
- 2. NK1 antagonist: Aprepitant 125mg PO Day 1, 80mg Days 2–3 (or Fosaprepitant IV 150mg Day 1)
- 3. Dexamethasone: 12mg IV Day 1 (reduce if NK1 antagonist used — CYP450 interaction), 8mg Days 2–3
- Breakthrough antiemetic: Metoclopramide 10mg QID or Prochlorperazine — prescribe PRN
- Lorazepam: 0.5–1mg PO/IV for anticipatory nausea
- Assess CINV at every cycle using MASCC antiemesis tool
- Document nausea/vomiting frequency, severity (CTCAE Grade 1–4)
Renal Function & Ototoxicity Monitoring
Nephrotoxicity
- Weekly creatinine/eGFR check — mandatory before each cisplatin dose
- Hold cisplatin if creatinine rise >20% from baseline or eGFR <50ml/min/1.73m²
- CTCAE Grade ≥2 renal toxicity → dose reduction or switch to carboplatin/cetuximab
- Avoid concurrent nephrotoxins: NSAIDs, aminoglycosides, IV contrast (liaise with radiology)
- Maintain good hydration between cisplatin cycles — advise patients 2L/day fluid intake
Ototoxicity
- Audiogram before treatment starts — baseline essential
- Weekly audiogram for cumulative cisplatin toxicity during CRT
- CTCAE Grading: Grade 1: threshold shift ≥15dB; Grade 2: intervention indicated; Grade 3: limiting self-care; Grade 4: profound bilateral hearing loss
- Grade ≥2: discuss with oncologist — dose modification/switch to cetuximab
- Cumulative cisplatin dose >300mg/m² = high ototoxicity risk
- Paediatric and young patients: especially vigilant (developmental impact)
Cetuximab Rash Management
Acneiform Rash — Grading
| Grade | Description | Action |
|---|
| 1 | Papulopustular <10% BSA | Topical clindamycin 1% / hydrocortisone |
| 2 | 10–30% BSA | Oral doxycycline 100mg BD + topical; dose delay if needed |
| 3 | >30% BSA or secondary infection | Dose hold; IV antibiotics if infected; dermatology review |
| 4 | Life-threatening superinfection | Permanently discontinue cetuximab |
Skin Care for Cetuximab Rash
- Prophylactic doxycycline 100mg BD from Day 1 (reduces Grade ≥2 rash incidence)
- High-SPF sunscreen (SPF 50+) from Day 1 — sun exacerbates rash significantly
- Avoid alcohol-based skincare, exfoliants, hot showers
- Thick emollient (e.g., white soft paraffin) to dry/peeling areas
- Patient education: paradoxically, rash correlates with tumour response — reassurance important
- Infusion reactions: premedicate with chlorpheniramine + hydrocortisone before every dose
Nutritional Support During CRT
⚠MANDATORY: Dietitian review every week during CRT. Weight loss >5% body weight in any 3-week period during treatment is a threshold for enteral feeding escalation.
Nutritional Targets During CRT
- Energy: 30–35 kcal/kg/day (35–40 if malnourished)
- Protein: 1.5–2.5g/kg/day (higher during CRT due to tissue repair demands)
- Weigh patient twice weekly
- Document oral intake (24h food diary or estimated calorie count)
- Trigger for NGT: <60% estimated requirements for >3 days OR >5% weight loss
Enteral Feeding During CRT
- NG tube: first-line acute setting; change every 4 weeks or per protocol
- PEG: preferred if CRT anticipated to cause severe mucositis (base of tongue, NPC, hypopharynx)
- Continue oral intake alongside tube feeding when possible — prevents swallowing disuse
- Goal: achieve full nutritional requirements via tube if oral <60%; allow oral top-up
- Monitor for aspiration if oral intake attempted — SLT assessment
Communication & Swallowing Rehabilitation
Communication Options Post-Laryngectomy
Tracheoesophageal Prosthesis (TEP) — Provox Valve
- Mechanism: One-way valve from trachea to oesophagus; patient occludes stoma (finger/HME), air diverted through prosthesis, vibrates pharyngo-oesophageal segment → voice
- Best voice quality of all methods — most natural; 80–90% of suitable patients achieve fluent speech
- Nursing: Daily cleaning routine: Brush prosthesis with provided brush 2–3× daily; flush with 5ml water syringe; use cleaning rod (Provox Flush tube)
- Prosthesis lifespan: Average 3–6 months; replace when leakage through prosthesis occurs
- Signs of failure: coughing/choking when drinking, voice deterioration, leakage around device
- CNS/SLT should change prosthesis — nurse-led change programmes exist in specialist centres
🚨TEP DISLODGEMENT EMERGENCY: If prosthesis falls out, the tract closes within hours. Cover stoma with tape/HME to prevent closure. Do NOT wait — proceed to Emergency Department or CNS immediately for replacement or tract dilation.
Electrolarynx & Oesophageal Speech
Electrolarynx
- Electronic device generating sound vibration — placed against cheek or submental area
- Immediate post-operative communication — use from day of recovery
- Articulation of words is normal — only sound source changes
- Teaching points: Device placement (find resonance point), button timing (press at start of word), clear articulation, use in quiet environments initially
- Models: Servox, TruTone, NuVois — available across GCC; check local supplier
- Disadvantage: mechanical sound, hands required, battery dependence
Oesophageal Speech
- Air injected/inhaled into oesophagus; controlled release vibrates pharyngo-oesophageal segment
- Requires intensive SLT training — months; success rate ~30%
- Hands-free — useful for patients unable to use TEP/electrolarynx
- Not suitable for patients with pharyngeal stricture or post-RT fibrosis
Swallowing Rehabilitation Post-RT/Surgery
Assessment — VFSS (Videofluoroscopic Swallowing Study)
- Gold standard assessment of swallowing function — dynamic X-ray study
- Guided by SLT — assesses each phase of swallow
- Identifies: aspiration (silent or overt), residue, timing abnormalities
- Nursing role: Explain procedure, position correctly, accompany if needed, document SLT recommendations in care plan
- Functional Oral Intake Scale (FOIS) — document level at each assessment
- IDDSI framework: texture levels 0 (thin liquid) to 7 (regular food) — use consistently
Swallowing Techniques
- Mendelsohn Manoeuvre: Voluntarily sustain laryngeal elevation at peak of swallow — improves UES opening and pharyngeal clearance
- Masako (Tongue-Hold) Exercise: Hold tongue between teeth during dry swallow — strengthens base of tongue retraction
- Supraglottic Swallow: Breath hold before and during swallow, cough after — protects airway in reduced laryngeal closure
- Effortful Swallow: Squeeze hard during swallow — increases tongue base pressure
Return of Swallowing Post-RT Timeline
| Timeframe | Expected function |
|---|
| End RT (Wk 7) | Peak dysphagia — usually tube-dependent |
| 4–6 wks post-RT | Mucositis resolving, begin oral trials with SLT |
| 3 months | Most can manage soft/minced diet; weaning off tube |
| 6 months | 60–70% return to near-normal swallowing (base of tongue — lower rates) |
| 12+ months | Plateau — ongoing SLT for residual dysphagia, consider dilation/botox to UES stricture |
Nutritional Rehabilitation Post-RT
- Gradual texture transition using IDDSI framework — SLT directed
- High-calorie oral supplements (Fortisip, Ensure Plus) during transition off tube
- Monitor weight weekly; maintain tube until 75–80% nutritional requirements met orally
- Taste recovery: gradual, typically 6–12 months; zinc supplementation (45mg elemental Zn daily) — evidence for taste recovery
Psychological Support & Quality of Life
Key Psychological Challenges
- Body image: Neck scar, stoma, tracheostomy, facial changes, weight loss — address proactively
- Voice loss: Identity, professional life, relationships — most distressing for many patients; validate grief
- Eating difficulties: Social isolation — cannot eat normally with family; deeply significant in GCC family culture
- Fear of recurrence: Every scan causes anxiety; normalise, provide contact information
- Sexual function: Often not raised by patients — ask sensitively; neck dissection/RT affects sensation, intimacy
- Employment: Voice loss may end career (teachers, call centre, sales) — social work referral
Support Resources in GCC
- Peer support groups: Laryngectomy support groups (present in major GCC centres — Dubai, Abu Dhabi, Riyadh, Doha); connect patients pre-operatively with laryngectomee volunteer speakers
- Multilingual resources: Tagalog, Hindi, Urdu, Bahasa resources needed for GCC's dominant expat groups — advocate for translation
- Arabic resources: Voice prosthesis instruction sheets available in Arabic — ensure these are provided; some patients literate in Arabic only
- Online communities: WebWhispers International Laryngectomee support online community — accessible from GCC
- Psychological support: Clinical psychologist referral threshold should be low — not only for crisis; proactive referral at diagnosis and post-treatment
GCC-Specific Head & Neck Cancer Context
High-Risk Populations in GCC
| Group | Cancer Risk | Risk Factor |
|---|
| Filipino, Thai, Malaysian, Vietnamese workers | Nasopharyngeal (NPC) | EBV-driven; endemic background prevalence; genetic susceptibility |
| South Asian workers (Indian, Pakistani, Bangladeshi, Sri Lankan) | Oral cavity SCC | Tobacco/betel nut/gutka/paan chewing — areca nut carcinogen |
| Yemeni expats/residents | Oral cavity SCC | Qat (khat) chewing — Catha edulis; alkaloids cause mucosal irritation; often held in buccal sulcus |
| All male GCC population (residents and expats) | Laryngeal/hypopharyngeal | Shisha/hookah/waterpipe smoking — equivalent to 100+ cigarettes per session in some studies |
| GCC nationals and expats with outdoor work | Cutaneous SCC/BCC (head/neck) | Extreme UV exposure — GCC has some of world's highest UV index values |
| Eastern European expats (post-Chernobyl regions) | Thyroid cancer | Childhood radiation exposure in Belarus, Ukraine, Russia; iodine deficiency compounding factor |
Tobacco & Substance Risk Factors in GCC
- Areca nut (betel nut) is a Group 1 carcinogen (IARC) — independent of tobacco
- Paan: areca nut + betel leaf ± tobacco; Gutka: dry preparation with tobacco; Mawa: areca + tobacco + slaked lime
- Oral submucous fibrosis (OSF): precancerous condition from areca nut; trismus + mucosal rigidity; 5–10% malignant transformation risk
- Extremely common among South Asian communities in UAE, Qatar, Kuwait, Saudi Arabia, Bahrain
- Nursing: Non-judgmental assessment of chewing habit; provide Urdu/Hindi cessation materials; refer to tobacco/substance cessation service; examine buccal mucosa for leukoplakia/erythroplakia at every visit
- Catha edulis — stimulant plant; chewed for hours, held in buccal pouch
- Common in Yemeni, Ethiopian, Somali communities; technically illegal in most GCC states but used by some communities
- Chronic mucosal irritation → oral leukoplakia; probable oral cavity carcinogen
- Cultural significance — social ritual; cessation requires culturally sensitive approach
- Nursing: Screen for oral lesions; sensitive enquiry about qat use; involve cultural liaison worker where available
- Waterpipe smoking highly prevalent across all GCC demographics — falsely perceived as "safer" than cigarettes
- One hookah session = 100–200 cigarette equivalent smoke volume exposure
- Carbon monoxide, heavy metals, polycyclic aromatic hydrocarbons — same or higher levels than cigarettes
- Associated with oral, laryngeal, hypopharyngeal, lung cancers
- Nursing myth-busting: Water filtration does NOT remove carcinogens; educate patients and families; social pressure in GCC to participate — address community norms
Thyroid Cancer in GCC
- Rising incidence across GCC — partly attributable to increased ultrasound screening detecting small papillary thyroid cancers
- Iodine supplementation programmes: Mandatory salt iodisation in GCC countries — may paradoxically increase papillary thyroid cancer incidence (iodine-sufficient environment shifts balance toward papillary histology)
- Genetic factors: RET/PTC rearrangements; BRAF V600E mutation common in papillary thyroid cancer
- Eastern European expats (Ukraine, Belarus, Russia) — childhood exposure to radioiodine fallout from Chernobyl (1986); higher thyroid cancer risk; present middle-aged in GCC now
- Papillary thyroid cancer: Excellent prognosis; surgery (total thyroidectomy ± neck dissection) + radioiodine (I-131) if indicated; TSH suppression with levothyroxine post-surgery
- Nursing post-thyroidectomy:
- Hypocalcaemia monitoring: tingling (Chvostek/Trousseau signs), Ca²⁺ every 4–6h post-op, calcium supplementation protocol
- Haematoma: airway emergency — rapid expanding neck swelling post-op requires emergency re-exploration
- RLN injury: hoarseness assessment post-op — refer ENT if persistent
- Levothyroxine education: take fasting, consistent timing, lifelong compliance
Cultural & Religious Considerations in GCC Head & Neck Cancer Care
Islamic Prayer (Salah) Adaptations for Laryngectomy
- Wudu (ritual ablution) with stoma: Mainstream Islamic scholarly opinion — wudu remains valid; care must be taken not to allow water entry into stoma during face washing; waterproof stoma cover or HME during wudu; many scholars permit covering stoma with hand during face wash sequence
- Patient counselling: Reassure that Islamic scholars have addressed this; print verified fatwas in patient language; refer to hospital chaplain/imam if patient distressed
- Prayer positions (ruku/sujood): Stoma care — ensure HME in place during prostration; stoma position not obstructed by prayer mat contact
- Ramadan fasting with NG/PEG tube: Complex Islamic jurisprudence; most scholars permit tube feeding as medical necessity; hospital imam consultation recommended; involves both spiritual and clinical team
Head Covering, Scar Concealment & Body Image
- Neck dissection scar: For female patients wearing hijab — scarf can provide natural concealment; some patients find this reassuring; SLT/CNS discuss before surgery
- Post-laryngectomy stoma: Stoma visibility under loose clothing; discrete HME covers available; laryngectomy bibs in skin tones; fashion/clothing adaptations — CNS aware of resources
- Arabic-language resources: Voice prosthesis instruction, post-laryngectomy care, RT side effect management — demand hospital provides Arabic translations
- Family communication: In many GCC families, relatives wish to be informed first before patient; navigate carefully — respect patient autonomy while being culturally sensitive; document patient's preference about information sharing
- Gender: Female patients may prefer female nurse for intimate stoma care — document and accommodate where possible
GCC Head & Neck Cancer Nursing Guide — For qualified nursing professionals. Always follow local institutional protocols. Not a substitute for clinical judgement. Updated 2026.